Navigation Links
CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
Date:10/20/2008

HARBIN, China, Oct. 20 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" or "the Company"), a leading provider in the health and nutritional food industry engaged in the development, manufacture and distribution of nutritional food products, dietary supplements, and raw cactus plants in the People's Republic of China ("PRC"), today announced that the Company's Chief Financial Officer Ren Hu was interviewed by the Wall Street Transcript to discuss the Company's growth strategy involving its organic and health food business. The interview was published October 20, 2008.

In the interview, Mr. Hu stated that the demand for organic and health food in China is propelled by the increasing disposable income of Chinese urbanites, along with concerns over food safety. China Yingxia has actively focused on growing its nutritional food segment to address this demand. The recent acquisition of a soy milk production facility in Shanghai was a step in this direction, as it equipped the Company with advanced food processing technology for the production of soy milk and soy yogurt.

On addressing the recent scandal involving contaminated cow's milk in China, Mr. Hu considered it to be an opportunity for China Yingxia, since the Company's products are soybean based milk and yogurt, while the majority of the tainted products were derived from cow's milk. The Company's integrated business model and rigid quality control procedures also prevent harmful substances from entering the production process. Soy milk is believed to have more health benefits and a scandal like this may urge more consumers to look for alternatives to cow's milk. China Yingxia will start a marketing campaign to position the Company's organic and health food products attractively to the consumers.

"China Yingxia follows two main strategies to expand its market," Mr. Hu stated in the interview. "The first is to expand the distribution network by adding more stores via proper marketing campaigns and promotions. The second strategy is to grow through acquisitions to break geographical barriers."

About China Yingxia International, Inc.

China Yingxia International, Inc., through its 100%-owned subsidiary, Harbin Yingxia Industrial Group Co., Ltd. ('Yingxia'), is primarily engaged in the development, production and sales of health food products in China. Yingxia is located in the Province of Heilongjiang, Peoples Republic of China. Yingxia's products include soybean-based foods and drinks, longgu golden millet enriched products, organic rice products, raw cacti, cactus and other herbal-based supplements, cosmetics, personal care products, and Nestle products.

Safe Harbor Statement

The statements contained herein that are not historical facts are 'forward-looking statements' within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as 'believes,' 'expects,' 'may,' 'will,' 'should,' or 'anticipates,' 'expect' or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets or forecasting financial results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Company Contact:

Mr. Ren Hu

Chief Financial Officer

China Yingxia International, Inc.

Tel: +1-201-887-0415

Email: arenhu@gmail.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Yingxia International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
2. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
3. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
4. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
5. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
6. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
7. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
8. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
9. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
10. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
11. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... Delpor, ... a $224K grant from the National Institute of Mental Health (NIMH) for the further ... on Delpor’s PROZOR technology and is expected to deliver therapeutic levels of ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):